Background
Conventional therapy
Novel agents and relevant combination therapies
Histone deacetylase inhibitors
Immunoconjugates
Antifolates
Monoclonal antibodies
Immunomodulatory agents
Nucleoside analogs
Proteasome inhibitors
Kinase inhibitors
Bendamustine
l-asparaginase
Other targeted agents
Agent | Targeting site | Phase | No. of evaluable patients | Type of patients | Outcomes | ClinicalTrial.gov ID | References |
---|---|---|---|---|---|---|---|
Tipifarnib | Farnesyltransferase inhibitor | II | 12 | PTCL | 50 % ORR | NCT00082888 | [49] |
Darinaparsin | Organic arsenic compound | II | 7 | PTCL | 28.6 % ORR, 3.6 months median TTF, 6.4 months OS | NCT00421213 | [50] |
Panobinostat | Pan-deacetylase inhibitor | II | 139 | CTCL | 17.3 % ORR | NCT00425555 | [51] |
Denileukin diftitox | Interleukin fusion protein | III | 263 | CTCL | 38 % ORR, median DoR was 277 days | NCT00050999 | [52] |
NCT00051012 | |||||||
Ixazomib | Proteasome inhibitor | I | 4 | PTCL | 1 PR | NCT00893464 | [53] |
Sorafenib | Multikinase inhibitor | — | 12 | PTCL/CTCL | 42 % ORR, 4 CR, 1 PR | — | [54] |
Forodesine | PNP inhibitor | II | 101 | CTCL | No CR, 11 % PR, 50 % SD, median DoR was 191 days | NCT00501735 | [55] |
Agent | Targeting site | Phase | ClinicalTrial.gov ID |
---|---|---|---|
Endostar | Angiogenesis inhibitor | II | NCT02520219 |
Selinexor | Selective inhibitor of nuclear export | II | NCT02314247 |
Tipifarnib | Farnesyltransferase inhibitor | II | NCT02464228 |
Darinaparsin | Organic arsenic compound | I | NCT01435863 |
NCT01689220 | |||
Ixazomib | Proteasome inhibitor | II | NCT02158975 |
Denileukin diftitox | Interleukin fusion protein | II | NCT00050999 |
NCT00051012 | |||
Forodesine | PNP inhibitor | I/II | NCT01776411 |
Ruxolitinib | JAK inhibitor | II | NCT01431209 |
Temsirolimus | mTOR inhibitor | I | NCT01614197 |
Carfilzomib | Proteasome inhibitor | I | NCT01336920 |
Panobinostat | Pan-deacetylase inhibitor | II | NCT01261247 |
Clofarabine | DNA synthesis inhibitor | I/II | NCT00644189 |
MK2006 | AKT inhibitor | II | NCT01258998 |
Sorafenib | Multikinase inhibitor | II | NCT00131937 |
Alefacept | Immunosuppressive dimeric fusion protein | I | NCT00438802 |
Pembrolizumab | PD-1 antibody | II | NCT02535247 |